相关实验视频

Updated: Jun 10, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on ¹⁸F-AV-1451

Published on: April 18, 2025

默认模式网络tau预测未来的非典型早期阿尔茨海默病的临床下降

Yuta Katsumi^1,2,3, Inola A Howe¹, Ryan Eckbo¹

¹Frontotemporal Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.

Brain : a journal of neurology

|October 16, 2024

概括

默认模式网络中的TAU PET成像预测了早期阿尔茨海默病的临床衰退. 这种成像生物标志物有助于对非典型的AD患者进行个性化的预后和治疗计划.

科学领域:

神经成像是一种神经成像.
神经学神经学
生物标志物生物标志物

背景情况:

早期识别患有阿尔茨海默病 (AD) 患者的风险迅速下降对于明智的决策至关重要.
虽然TAU PET在典型的AD中具有预后作用,但它在非典型的AD表型中的作用不明.
非典型的AD患者在默认模式网络 (DMN) 中显示tau积累,表明其作为常见预后生物标志物的潜力.

研究的目的:

调查基线TAU PET信号与非典型早期AD患者随后临床衰退之间的关系.
确定DMN中的tau负担是否是不同非典型AD表型中临床进展的可靠预测指标.

主要方法:

这项研究包括48名患有轻度认知障碍或轻度痴呆症的患者,这些患者患有非典型的表型 (后皮层缩,logopenic变体初级渐进性失声症,年轻发病的amnestic AD).
所有参与者都接受了基线MRI,TAU PET和粉样蛋白PET扫描.
用临床痴呆症评分总和 (CDR-SB) 分数的年化变化来评估长度临床下降,平均随访时间为14.55个月.

主要成果:

非典型的早期AD患者在CDR-SB得分中每年显著增加 (1.18 ± 1.25分/年).
在DMN的基线tau是临床衰退的最强预测因素 (R2 = 0.30).
基于临床障碍,人口统计,其他网络中的tau,皮质缩和DMN粉样蛋白负担的模型,DMN tau的表现优于模型.

结论:

默认模式网络tau积累是非典型早期AD临床衰退的重要预测因素.
这种TAU PET测量提供了一个个性化的预后工具,用于预测疾病进展.
研究结果支持使用DMNPET用于非典型AD的个性化预后,监测和治疗计划.

关键词:

大脑皮层大脑皮层早期发病的阿尔茨海默氏病.神经退行症的神经退行症神经成像是一种神经成像.位置排放断层扫描 (PET) 是一种位置排放断层扫描.病理学病理学

更多相关视频

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid

Published on: September 3, 2021

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Dementia

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....

Long-term Depression

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...